Biogen shares decline as ICER panel unanimously votes Aduhelm lacks clinical benefit -- STAT

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Biogen shares decline as ICER panel unanimously votes Aduhelm lacks clinical benefit -- STAT

To read the full story on Seeking Alpha, click here.

Biogen (NASDAQ:BIIB)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Biogen Charts.

Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Biogen Charts.

Biogen Inc News

Investors who lost money on Biogen Inc. (BIIB) should contact The Gross Law Firm about pending Class Action - BIIB
Wednesday 5 June 2024 (4 days ago) • PR Newswire (US)

Economic Worries May Lead To Weakness On Wall Street
Tuesday 4 June 2024 (5 days ago) • IH Market News

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
Monday 3 June 2024 (6 days ago) • GlobeNewswire Inc.

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
Friday 31 May 2024 (1 week ago) • GlobeNewswire Inc.

OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News
Thursday 23 May 2024 (2 weeks ago) • IH Market News

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Wednesday 22 May 2024 (3 weeks ago) • GlobeNewswire Inc.

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Thursday 16 May 2024 (3 weeks ago) • GlobeNewswire Inc.

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Thursday 16 May 2024 (3 weeks ago) • PR Newswire (US)

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Wednesday 15 May 2024 (4 weeks ago) • GlobeNewswire Inc.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Wednesday 15 May 2024 (4 weeks ago) • PR Newswire (US)

Biogen Reports Progress on Corporate Responsibility Priorities
Thursday 2 May 2024 (1 month ago) • GlobeNewswire Inc.

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Monday 1 April 2024 (2 months ago) • PR Newswire (US)

More Biogen Inc News Articles

IN XTMSCI EM CLITRALS

BNP Paribas Asset Manage...

Polymetals Resources

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions